These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 17614878)

  • 1. Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.
    Medina-Tato DA; Ward SG; Watson ML
    Immunology; 2007 Aug; 121(4):448-61. PubMed ID: 17614878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease.
    Marwick JA; Chung KF; Adcock IM
    Ther Adv Respir Dis; 2010 Feb; 4(1):19-34. PubMed ID: 20051446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases.
    Ghigo A; Damilano F; Braccini L; Hirsch E
    Bioessays; 2010 Mar; 32(3):185-196. PubMed ID: 20162662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
    Rommel C; Camps M; Ji H
    Nat Rev Immunol; 2007 Mar; 7(3):191-201. PubMed ID: 17290298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of class I phosphoinositide 3-kinase in T-cell function and autoimmunity.
    Fruman DA
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):177-80. PubMed ID: 17371231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation to Pulmonary Diseases.
    Lee KY; Ito K; Maneechotesuwan K
    Mediators Inflamm; 2016; 2016():7401245. PubMed ID: 27293320
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
    Foster JG; Blunt MD; Carter E; Ward SG
    Pharmacol Rev; 2012 Oct; 64(4):1027-54. PubMed ID: 23023033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives.
    Vyas P; Vohora D
    Curr Drug Targets; 2017; 18(14):1622-1640. PubMed ID: 27739372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting phosphoinositide 3-kinase gamma to fight inflammation and more.
    Barberis L; Hirsch E
    Thromb Haemost; 2008 Feb; 99(2):279-85. PubMed ID: 18278175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K signaling in arterial diseases: Non redundant functions of the PI3K isoforms.
    Lupieri A; Smirnova N; Malet N; Gayral S; Laffargue M
    Adv Biol Regul; 2015 Sep; 59():4-18. PubMed ID: 26238239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoinositide 3-kinase in immunological systems.
    Fruman DA; Cantley LC
    Semin Immunol; 2002 Feb; 14(1):7-18. PubMed ID: 11884226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary macrophages: key players in the innate defence of the airways.
    Byrne AJ; Mathie SA; Gregory LG; Lloyd CM
    Thorax; 2015 Dec; 70(12):1189-96. PubMed ID: 26286722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukocyte navigation mechanisms as targets in airway diseases.
    Medina-Tato DA; Watson ML; Ward SG
    Drug Discov Today; 2006 Oct; 11(19-20):866-79. PubMed ID: 16997136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphoinositide 3-kinase: a critical signalling event in pulmonary cells.
    Condliffe AM; Cadwallader KA; Walker TR; Rintoul RC; Cowburn AS; Chilvers ER
    Respir Res; 2000; 1(1):24-9. PubMed ID: 11667961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma.
    Park SJ; Min KH; Lee YC
    Respirology; 2008 Nov; 13(6):764-71. PubMed ID: 18811876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphoinositide 3-kinase δ (PI3Kδ) in respiratory disease.
    Stokes CA; Condliffe AM
    Biochem Soc Trans; 2018 Apr; 46(2):361-369. PubMed ID: 29523773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K Signaling in Chronic Obstructive Pulmonary Disease: Mechanisms, Targets, and Therapy.
    Pirozzi F; Ren K; Murabito A; Ghigo A
    Curr Med Chem; 2019; 26(16):2791-2800. PubMed ID: 29557740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging role of myeloid-derived suppressor cells in lung diseases.
    Kolahian S; Öz HH; Zhou B; Griessinger CM; Rieber N; Hartl D
    Eur Respir J; 2016 Mar; 47(3):967-77. PubMed ID: 26846830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoinositide 3-kinase signalling in the vascular system.
    Morello F; Perino A; Hirsch E
    Cardiovasc Res; 2009 May; 82(2):261-71. PubMed ID: 19038971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining Bronchial Asthma with Phosphoinositide 3-Kinase Delta Activation: Towards Endotype-Driven Management.
    Jeong JS; Kim JS; Kim SR; Lee YC
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31323822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.